Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)

Key Points

• Wedbush reiterated an "Outperform" rating on Perspective Therapeutics with an $11 price target (implying roughly 193% upside), and the consensus analyst target sits at $12.63 with most firms rating the stock a Buy.
• Shares slid 5.7% to $3.76 on Tuesday, trading well below analyst targets; the company reported a quarterly loss (EPS -$0.51), only $0.04M in revenue, and very negative margins and return on equity.
• Perspective Therapeutics is developing precision-targeted alpha therapies for oncology, with lead programs VMT-a-NET and VMT01 currently in Phase 1/2a trials for SSTR2-expressing tumors and metastatic melanoma.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "outperform" rating reiterated by equities researchers at Wedbush in a report issued on Tuesday,Benzinga reports. They currently have a $11.00 price objective on the stock. Wedbush's target price would suggest a potential upside of 192.94% from the stock's current price.

Several other brokerages have also recently commented on CATX. B. Riley Financial boosted their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, March 18th. Piper Sandler assumed coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an "overweight" rating and a $16.00 price target on the stock. HC Wainwright boosted their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Monday, March 23rd. UBS Group boosted their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday, March 18th. Finally, Royal Bank Of Canada cut their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat.com, Perspective Therapeutics currently has an average rating of "Buy" and a consensus target price of $12.63.

Perspective Therapeutics Stock Down 5.7%

CATX traded down $0.23 during trading on Tuesday, hitting $3.76. The company had a trading volume of 531,118 shares, compared to its average volume of 2,852,555. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16. The firm's 50-day moving average price is $4.67 and its 200 day moving average price is $3.60. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.04 million during the quarter. As a group, equities research analysts predict that Perspective Therapeutics will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. AXQ Capital LP increased its stake in shares of Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company's stock worth $35,000 after purchasing an additional 2,481 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Perspective Therapeutics by 6.1% during the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company's stock worth $149,000 after purchasing an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of Perspective Therapeutics by 25.0% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $69,000 after purchasing an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock worth $29,000 after purchasing an additional 5,475 shares during the last quarter. Finally, Taylor & Morgan Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 6.6% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company's stock worth $267,000 after purchasing an additional 6,000 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.